Manuel Cobo
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 124
- Lung Cancer Diagnosis and Treatment 43
- Oncology 129
- Cancer Immunotherapy and Biomarkers 62
- Lung Cancer Research Studies 58
- Colorectal Cancer Treatments and Studies 20
- HER2/EGFR in Cancer Research 11
- Co-authors
- Bartomeu Massutí (39 shared papers)Tudor–Eliade Ciuleanu (8 shared papers)Tsveta Milenkova (3 shared papers)Gyula Ostoros (3 shared papers)Alan Webster (3 shared papers)Dolores Isla (38 shared papers)Enriqueta Felip (42 shared papers)Ki Hyeong Lee (9 shared papers)
- Journals
- Journal of Clinical Oncology (47 papers)Annals of Oncology (44 papers)Journal of Thoracic Oncology (30 papers)Lung Cancer (20 papers)Clinical & Translational Oncology (13 papers)
- Partner nations
- SpainUnited StatesFrance
In The Last Decade
Manuel Cobo
210 papers receiving 5.4k citations
Manuel Cobo's Hit Papers
Peers
Comparison fields: 5 of 101
- Oncology 2.9k
- Pulmonary and Respiratory Medicine 2.8k
- Cancer Research 859
- Immunology 490
- Otorhinolaryngology 65
Countries citing papers authored by Manuel Cobo
This map shows the geographic impact of Manuel Cobo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuel Cobo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuel Cobo more than expected).
Fields of papers citing papers by Manuel Cobo
This network shows the impact of papers produced by Manuel Cobo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuel Cobo. The network helps show where Manuel Cobo may publish in the future.
Co-authors
The 25 scholars most cited alongside Manuel Cobo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 224 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2018 | 534 |
| 2 | 2007 | 361 | |
| 3 | Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status Hit paper breakdown → | 2014 | 356 |
| 4 | Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial Hit paper breakdown → | 2015 | 337 |
| 5 | First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study Hit paper breakdown → | 2013 | 331 |
| 6 | Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study Hit paper breakdown → | 2022 | 316 |
| 7 | Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial Hit paper breakdown → | 2020 | 301 |
| 8 | Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer Hit paper breakdown → | 2017 | 254 |
| 9 | 2020 | 195 | |
| 10 | 2006 | 150 | |
| 11 | 2020 | 106 | |
| 12 | 2018 | 102 | |
| 13 | 2018 | 82 | |
| 14 | 2019 | 80 | |
| 15 | 2015 | 70 | |
| 16 | 2010 | 68 | |
| 17 | 2020 | 51 | |
| 18 | 2018 | 48 | |
| 19 | 2019 | 46 | |
| 20 | 2021 | 45 |
About Manuel Cobo
Manuel Cobo is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 224 papers that have together received 5.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (124 papers), Cancer Immunotherapy and Biomarkers (62 papers), Lung Cancer Research Studies (58 papers), Lung Cancer Diagnosis and Treatment (43 papers), Cancer Genomics and Diagnostics (26 papers), Colorectal Cancer Treatments and Studies (20 papers), Cancer therapeutics and mechanisms (12 papers) and HER2/EGFR in Cancer Research (11 papers). The work is most often cited by research in Oncology (2.9k citations), Pulmonary and Respiratory Medicine (2.8k citations), Cancer Research (859 citations), Immunology (490 citations) and Otorhinolaryngology (65 citations). Manuel Cobo has collaborated with scholars based in Spain, United States and France. Frequent co-authors include Bartomeu Massutí, Tudor–Eliade Ciuleanu, Tsveta Milenkova, Gyula Ostoros, Alan Webster, Dolores Isla, Enriqueta Felip, Ki Hyeong Lee, Byoung Chul Cho and Fabrice Barlési. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer and Clinical & Translational Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.